Fontan Udenafil Exercise Longitudinal Assessment Trial (the FUEL-2 Study) Phase 3 study, to evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of phosphodiesterase type 5 (PDE5)